Domperidone

證據等級: L5

預測適應症: 10 個

Domperidone: From Nausea & Vomiting to Headache Disorder

One-Sentence Summary

Domperidone is a peripherally selective dopamine D2 receptor antagonist, widely used as an antiemetic and prokinetic agent for nausea, vomiting, and gastric motility disorders. The TxGNN model predicts it may be effective for Headache Disorder (particularly migraine), the highest-evidence prediction among the top 10 candidates, with 0 clinical trials and 20 publications currently supporting this direction.

Note on prediction ranking: TxGNN's top-ranked prediction by score is nephrogenic syndrome of inappropriate antidiuresis (NSIAD, score 99.08%), but this has no supporting clinical evidence and a mechanistic rationale that is directionally inconsistent with treatment goals (Hold). The headache disorder prediction (score 96.72%), while ranked 4th by model score, carries L3 evidence and a Proceed with Guardrails recommendation — making it the primary focus of this report.

Quick Overview

Item	Content
Original Indication	Nausea, vomiting, and gastric motility disorders (antiemetic/prokinetic)
Predicted New Indication	Headache Disorder (Migraine)
TxGNN Prediction Score	96.72%
Evidence Level	L3
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Domperidone is a dopamine D2 receptor antagonist that acts primarily at the chemoreceptor trigger zone (CTZ) and the upper gastrointestinal tract. Unlike metoclopramide, it is peripherally selective with minimal CNS penetration, which limits extrapyramidal side effects while preserving both antiemetic and prokinetic activity.

Migraine attacks are frequently accompanied by nausea, vomiting, and gastric stasis — pathophysiological features that domperidone is mechanistically well-positioned to address. During a migraine attack, delayed gastric emptying significantly impairs oral absorption of analgesics and triptans. By restoring normal gastric motility, domperidone acts as a pharmacokinetic enhancer for co-administered acute migraine medications. This "adjunct role" is recognised in multiple major guidelines, including the Canadian Headache Society (2013) and European treatment recommendations, and is directly supported by an RCT comparing domperidone + paracetamol (Domperamol) to sumatriptan 50 mg in moderate-to-severe migraine.

Beyond its symptomatic role, emerging 2024 evidence (Karsan & Goadsby, CNS Drugs) proposes that dopaminergic activation during the premonitory phase is a key migraine trigger mechanism. Blocking D2 receptors in this pre-headache window may prevent the cascade from progressing to full attack — an early-intervention hypothesis that positions domperidone not merely as an adjunct, but potentially as a disease-modifying agent when administered in the prodrome. The mechanistic link is rated moderate-to-strong.

Clinical Trial Evidence

Currently no related clinical trials registered on ClinicalTrials.gov or ICTRP for this drug-indication pair.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
11191009	2000	RCT	Current Medical Research and Opinion	Domperidone + paracetamol (Domperamol) vs sumatriptan 50 mg in moderate-to-severe migraine (n=120, UK primary care); comparable efficacy and tolerability
27837002	2016	Prospective Safety Study	Neurology	Safety evaluation of domperidone for nausea management during dihydroergotamine (DHE) infusion in refractory headache; favourable safety profile reported
33409110	2020	Prospective Observational	Cureus	Real-world headache management study from tertiary care; documents domperidone use in clinical migraine practice with disability assessment (MIDAS, VAS, HIT-6)
23968886	2013	Clinical Guideline	Canadian Journal of Neurological Sciences	Canadian Headache Society acute migraine guideline; explicitly includes domperidone as a recommended antiemetic adjunct for episodic migraine
38822165	2024	Review	CNS Drugs	Premonitory phase intervention in migraine; D2 antagonists (including domperidone) proposed as early-window treatment to prevent progression to headache onset
9876882	1998	Review	Cephalalgia	Pathophysiology of emesis in migraine; benzamide D2 antagonists (domperidone, metoclopramide) identified as central to antiemetic and prokinetic strategy in migraine
10494007	1999	Review	Canadian Journal of Clinical Pharmacology	Migraine-associated nausea; domperidone's prokinetic action shown to improve GI absorption of analgesics and triptans during attack
8749241	1995	Review	Cephalalgia	Analgesics and NSAIDs in acute migraine; domperidone 20 mg orally recommended as antiemetic adjunct to enhance drug resorption
25877672	2015	Review	Headache	Comprehensive review of acute migraine treatment in adults; prokinetic antiemetics including domperidone cited as validated adjunct strategy
11200800	2000	Review	Functional Neurology	Physiopharmacology of emesis and GI motility in migraine; details the mechanism by which domperidone restores retrograde GI contractions and improves drug delivery

Singapore Market Information

Domperidone (DB01184) is not currently registered with the Health Sciences Authority (HSA) of Singapore. No marketing authorisations were found in the HSA licensing database.

Practitioners should refer to EMA (European Medicines Agency) or Health Canada safety communications for current approved indications, warnings, and contraindication guidance, as domperidone is approved in multiple other jurisdictions (EU, Canada, Japan, Taiwan, among others).

Safety Considerations

Detailed TFDA/HSA package insert warnings and contraindications are not available in this Evidence Pack. Based on the published literature and known regulatory signals:

QT Prolongation Risk: Domperidone is a known QT-prolonging agent. The EMA and Health Canada have issued safety communications limiting use to the lowest effective dose and shortest duration, particularly in patients aged >60 years or receiving doses >30 mg/day.
Cardiac Risk: Observational studies have associated domperidone with increased risk of serious ventricular arrhythmia and sudden cardiac death, especially in combination with other QT-prolonging drugs (macrolide antibiotics, azole antifungals, HIV protease inhibitors).
Hyperprolactinaemia: As a D2 antagonist, domperidone elevates prolactin levels; prolonged use may cause galactorrhoea, amenorrhoea, and gynaecomastia.

Please refer to the EMA Public Assessment Report and package insert for complete safety information pending HSA regulatory review.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Domperidone has a well-characterised mechanistic basis and guideline-supported role in migraine management, backed by L3 evidence including one RCT (Domperamol vs sumatriptan) and multiple treatment guidelines; however, cardiac safety concerns (QT prolongation) and the absence of HSA registration in Singapore require a structured guardrail framework before any clinical deployment.

To proceed, the following is needed:

HSA registration pathway: Assess feasibility of HSA new drug application or off-label use framework in Singapore for migraine indication
Cardiac safety review: Mandatory QT-interval assessment protocol for any study design; exclude patients on concomitant QT-prolonging agents
Randomised controlled trial: Current RCT evidence (Domperamol, 2000) is underpowered and dated; a modern confirmatory trial with triptan comparator is needed
MOA documentation: Retrieve complete mechanism of action data from DrugBank (DG002) to support regulatory submission
TFDA/HSA package insert: Obtain and parse approved package insert for full contraindication and warning list (DG001, currently blocking S1 safety screening)
Drug interaction profile: Characterise DDI risk with co-prescribed migraine agents (triptans, ergotamines, NSAIDs) before any combination therapy study
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.